Metformin for Treatment of Fragile X Syndrome and Other Neurological Disorders

Area of Science:

• Neuroscience
• Genetics
• Pharmacology

Background:

• Fragile X syndrome (FXS) is the leading inherited cause of intellectual disability and autism spectrum disorder.
• Loss of fragile X mental retardation protein (FMRP) causes molecular, behavioral, and cognitive deficits in FXS.
• Animal models have significantly advanced understanding of FXS pathophysiology and identified therapeutic targets.

Purpose of the Study:

• To review the potential of metformin, an FDA-approved antidiabetic drug, for treating core symptoms of FXS.
• To explore metformin's efficacy in other human neurological disorders.
• To summarize metformin's mechanisms of action in various models of FXS and other diseases.

Main Methods:

• Review of existing literature on FXS.
• Analysis of studies using animal and cellular models of FXS.
• Examination of clinical data on metformin's effects in neurological disorders.

Main Results:

• Metformin demonstrates potential in preclinical models to address FXS-related deficits.
• The drug's mechanisms of action are being elucidated across different disease models.
• Evidence suggests possible applications beyond diabetes.

Conclusions:

• Metformin represents a promising therapeutic candidate for Fragile X syndrome.
• Further investigation into metformin's neurological effects is warranted.
• Repurposing metformin could offer a novel treatment strategy for FXS and related disorders.